1. Introduction {#sec1}
===============

Fanconi anemia (FA) is a rare inherited syndrome with diverse clinical symptoms including developmental defects, short stature, bone marrow failure, and a high risk of malignancies. Fifteen genetic subtypes have been distinguished: FA-A, -B, -C, -D1, -D2, -E, -F, -G, -I, -J, -L, -M, -N, -O, and -P. \[[@B1]--[@B4]\]. The majority of patients (\~85%) belong to the subtypes A (\~60%), C (\~10--15%), or G (\~10%), while a minority (\~15%) is distributed over the remaining 12 subtypes, with relative prevalences between \<1 and 5%. These percentages may differ considerably within certain ethnic groups, due to founder effects. All subtypes seem to fit within a "classical" FA phenotype, except for D1 and N (mutated in *BRCA2/FANCD1*and *PALB2/FANCN*), which are associated with a distinct, more severe, syndromic association. The mode of inheritance for all subtypes is autosomal recessive, except for FA-B, which is X-linked. These two different modes of inheritance have important consequences for the counseling of FA families. The relative prevalence of FA-B amongst unselected FA patients is estimated at 1.6% \[[@B5]\]. For all genetic subtypes disease genes have been identified ([Table 1](#tab1){ref-type="table"}). Many mutations found in the various subtypes are private, but recurrent mutations are known, particularly in specific ethnic backgrounds ([Table 2](#tab2){ref-type="table"}).

Most FA genes encode orphan proteins with no known molecular function. At least eight FA proteins (FANCA, -B, -C, -E, -F, -G, -L, and -M) assemble into a nuclear multiprotein core complex, which is required to activate FANCD2 and FANCI by monoubiquitination \[[@B6]\]. FANCL, which carries a RING finger domain, is supposed to represent the ubiquitin E3 ligase in this activation \[[@B7]\]. FANCM probably acts as a sensor of DNA damage and recruits the FA core complex to the site of damage, but FANCM also interacts with other proteins including Blm \[[@B6]\]. Monoubiquitination of FANCD2 and FANCI directs these proteins to areas of damaged chromatin where they interact with other proteins, resulting in repair of the damage \[[@B6]\]. The remaining FA proteins function downstream of or parallel to the FANCD2 activation step \[[@B6]\]. The exact nature of the DNA damage response, which when defective causes FA, remains to be defined. FANCJ/BRIP1 and FANCM possess DNA helicase motifs, which strongly suggests that the FA pathway acts through a direct interaction with DNA, presumably to resolve or remodel blocked DNA replication forks resulting from DNA interstrand cross-link damage \[[@B6]\]. This idea is strengthened by the recent extension of the FA pathway with SLX4, a scaffold protein for structure-specific endonucleases involved in unhooking the DNA cross-link \[[@B3], [@B4]\].

2. Laboratory Diagnostics in FA {#sec2}
===============================

Cells derived from FA patients are---by definition---hypersensitive to chromosomal breakage induced by DNA cross-linking agents such as mitomycin C (MMC) or diepoxybutane (DEB) \[[@B8]\]. This cellular phenotype is ascertained using stimulated blood T lymphocytes. The indications for FA laboratory testing are rather broad \[[@B9]\]. As a consequence, in only a small proportion of patients (about 10%) the chromosomal breakage test is positive, and an FA diagnosis is established. Since mutation testing by Sanger sequencing and MLPA is rather laborious, time consuming and therefore expensive, a positive chromosomal breakage test is a prerequisite for starting mutation screening. Confirmation of the FA diagnosis at the DNA level is important in patients in whom the chromosomal breakage test was inconclusive. Furthermore, knowledge about the FA subtype is relevant for the treatment and prognosis of the patients. In addition, identification of mutations allows carrier testing in the family and will enable prenatal DNA testing and preimplantation genetic diagnosis (PGD) in future pregnancies. Finally, this information can be used to rule out FA in potential donors for bone marrow transplantation.

Although simultaneous testing of all FA genes by next generation sequencing will be possible in the near future, this technique will not be available immediately for all laboratories worldwide. In addition, in populations with strong founder mutations, a limited test using Sanger sequencing and MLPA will be a cost-effective alternative \[[@B10]\]. The strategy outlined below has been developed at our DNA diagnostics laboratory to provide a molecular diagnosis of FA. It is recognized that mutations in *FANCA* account for 60--70% of all FA cases and that about 15--20% of the mutations in this gene are large deletions \[[@B10], [@B11]\]. Therefore, DNA testing usually starts with a screen for deletions in *FANCA*. However, depending on the circumstances strategies may differ from case to case.

2.1. Materials {#sec2.1}
--------------

Genomic DNA (from e.g., leukocytes or fibroblasts derived from the proband or the parents) is adequate for most mutation screening assays. Screening on cDNA is more efficient but has several drawbacks: for high-quality cDNA, growing cells (stimulated leukocytes, lymphoblastoid cell lines, or fibroblasts) are necessary. In addition, common alternative splice variants will hamper the evaluation of DNA sequences. Therefore, screening on gDNA is the preferred method for mutation screening. However, during the diagnostic process, growing cells from the proband will be helpful in a couple of situations. Growing cells are indispensable for studying the effect of unclassified variants on splicing or to verify the disease gene by functional complementation of the cellular phenotype with a construct expressing a wild type copy of the suspected gene \[[@B12]--[@B14]\]. Finally, if no mutations can be de detected, growing cells can be used to reconfirm the diagnosis FA by checking MMC sensitivity in cell growth or G2-arrest assays \[[@B15], [@B16]\].

2.2. Mutation Screening Strategy {#sec2.2}
--------------------------------

### 2.2.1. Hints from Ethnic Background or Phenotype {#sec2.2.1}

Information on the ethnic background of the proband may provide a clue for a specific pathogenic mutation that most likely causes the disease, such as c.711 + 4A \> T (IVS4 + 4A \> T) in *FANCC,* a mutation present in homozygous state in 80% of all FA cases of Ashkenazi Jewish ancestry, and c.295C \> T in *FANCA*, which was present homozygously in all 40 FA cases of Spanish Gypsy ancestry so far investigated. More examples of recurrent mutations are shown in [Table 3](#tab3){ref-type="table"}. The distinct clinical phenotype of D1 and N patients (severely affected, often combined with leukemia or solid tumors below the age of 5 years) may provide a clue to favor *BRCA2/FANCD1*and *PALB2/FANCN* as the first gene to be screened \[[@B17]--[@B21]\]. This is especially worthwhile if confirmed by the cellular phenotype: in contrast to cells from all other known FA subtypes, cells from D1, N and O patients are unable to form RAD51 foci upon exposure to X rays or MMC \[[@B20]--[@B22]\].

### 2.2.2. No Clues Available {#sec2.2.2}

1.  In the absence of any clue to the disease gene, mutation screening starts with a search for deletions in *FANCA*, as this type of mutation accounts for 40% of all mutant *FANCA* alleles. The quantitative multiplex ligation-dependent probe amplification (MLPA) method \[[@B23]\] is used for this initial screen, which identifies *FANCA* as the most likely disease gene in 1 out of 4 patients by the detection of a---usually hemizygous-deletion. In parallel, the *FANCA* gene is completely sequenced. The combination of these two approaches identifies 60--70% of all FA patients as FA-A.

2.  Next, *FANCC, -E, -F*, and *-G* are screened by DNA sequencing.

3.  Only if the proband is a male, *FANCB* is screened by MLPA and DNA sequencing,

In [Table 4](#tab4){ref-type="table"}, optimized conditions are provided for the PCR amplification of *FANCA, -C, -E, -F, -G, and -B*. Most PCRs can be performed under standard conditions. The PCR primers have M13 extensions which allow sequencing of all fragments with universal sequencing primers. MLPA was performed according to the instructions of the supplier. Detailed information about the sequences of the MLPA probes is available from the website of the supplier (<http://www.mlpa.com>). In a well-equipped laboratory with sufficient dedicated personal, testing of *FANCA, -C, -E, -F, -G and -B* can be completed within 1-2 weeks.

After screening *FANCA, -C, -E, -F, -G, and --B,* a molecular diagnosis is obtained for \~85% of the patients \[[@B11]\]. In our cohort of 54 patients, referred to our diagnostic service since 2008, mutations were detected in 45 patients (83%). *FANCA* mutations were found in 31 of the patients (57%), *FANCC* mutations in 6 patients (11%), and *FANCG* mutations in 5 patients (9%). *FANCB*, *FANCE,* and *FANCF* mutations were found in single families ([Table 3](#tab3){ref-type="table"}). In the small group of patients without mutations no complementation analysis or FANCD2 western blotting was performed. Therefore, we do not know if we missed *FANCA, -C, -E, -F, -G, and -B* mutations in these patients or that these patients have mutations in other FA genes. [Table 3](#tab3){ref-type="table"} does not include prenatal cases, because prenatal testing is only offered in couples in which the FA-causing mutations are already established. Testing was offered as a diagnostic service for which a fee was charged.

For the patients negative for *FANCA, -C, -E, -F, -G, and -B* mutations, next generation sequencing can be used to analyze all other FA genes. If this technique is not available, further analysis will depend on the availability of growing cells from the proband. In that case a western blot should reveal whether both FANCD2 isoforms are present at normal levels.

1.  If both FANCD2 bands are absent or very weak, *FANCD2*is sequenced. Because of the presence of *FANCD2* pseudogene sequences in the genome, this testing must be performed on cDNA or gDNA using specially designed primers \[[@B24]\].

2.  If only the short isoform of FANCD2 is present, *FANCL* and *FANCM* are sequenced. If no mutations are found, the patient may be mutated in *FANCI* or in another unidentified FA gene acting upstream of FANCD2.

3.  If both isoforms are present, and if the clinical phenotype is compatible with FA-D1 or FA-N, *BRCA2/FANCD1* and *PALB2/FANCN* are screened by MLPA and DNA sequencing.

4.  If negative, *BRIP1/FANCJ*, *PALB2/FANCN*, *RAD51C/FANCO,* and *SLX4/FANCP* are sequenced.

5.  If negative again, the patient should be screened for mutations in *NBS1*, *ESCO2* and *DDX11* to test for Nijmegen breakage syndrome, Roberts syndrome and Warsaw Breakage syndrome, respectively \[[@B25], [@B26]\]. The latter two syndromes can also be excluded by analyzing metaphase spreads for sister chromatid cohesion defects. If again negative, the patient is likely to be mutated in a novel FA gene acting downstream of FANCD2 ubiquitination.

3. Notes {#sec3}
========

3.1. Mutation Screening in Mosaic Patients {#sec3.1}
------------------------------------------

If an available lymphoblastoid cell line from an FA patient is phenotypically normal due to genetic reversion at the disease locus, mutation screening is still possible in the reverted cell line, since at least one mutation will be present \[[@B27]--[@B29]\]. The second mutation may be identified through investigating the parents.

3.2. Unclassified Variants {#sec3.2}
--------------------------

Missense mutations or *in-frame* deletions or insertions should be judged using *in silico* prediction algorithms (SIFT, POLYPHEN2, Align GVGD). Alternatively, they can be tested for pathogenicity in a cellular transfection assay to check the ability of the variant gene product to complement the cellular FA defect in a deficient cell line (see e.g., \[[@B30], [@B12], [@B31]\]). Generally, these tests are only feasible in a setting where a diagnostic laboratory is equipped with a research laboratory with all necessary technology.

3.3. Functional Assignment to Genetic Subtypes {#sec3.3}
----------------------------------------------

Retroviral constructs have been used to identify the FA subtype by functional complementation, as an intermediate step before a mutation screen is undertaken \[[@B13]\]. Although knowing the disease gene facilitates mutation screening, retroviral transduction has some drawbacks in comparison to direct mutation screening: (i) growing, MMC-sensitive cells either from a cell line or fresh blood sample are required, which are not always easy to obtain; (ii) overexpression of some FA proteins (e.g., FANCM and FANCP) may be toxic for cells; (iii) novel genetic subtypes that emerge after all known groups have been excluded and cannot be readily distinguished from false negatives, that is, transductions that for some unknown reason have failed to cause complementation; (iv) the method requires relatively advanced laboratory facilities and technology. However, functional assignment of complementation group can rapidly be provided by laboratories with capability for this type of analysis \[[@B14]\], which has greatly facilitated reliable genotyping for over 95% of FA patients for which viral constructs are available.

3.4. Genetic Counseling {#sec3.4}
-----------------------

All patients with a diagnosis of FA confirmed by mutation analysis should be referred for genetic counselling, together with their parents and siblings. Mutation testing should be performed in all sibs regardless of any clinical symptoms. A complete pedigree, including a cancer history anamnesis, should be prepared. Mutation carriers might be at increased cancer risk (see [Section 3.7](#sec3.7){ref-type="sec"}) whose aspect should be included in the counseling (see [Section 3.7](#sec3.7){ref-type="sec"}).

FA patients themselves usually have decreased fertility. Women usually have late menarche, irregular menses, and early menopause. However, pregnancies in women with FA have been described, and therefore women should be adequately informed about the risks for their offspring, which is mainly related to an increase in pregnancy-related complications \[[@B32]\].

Sibs of the parents of an FA patient often request carrier screening to assess their risk of getting a child with FA. If a sib appears to be carrier, this risk is still minimal because of the very low carrier frequency in the population. In the US the carrier frequency has been estimated to be about 1 in 181 \[[@B33]\]. The risk of a proven carrier to get a child with FA is therefore about 1 in 724. However, in small communities or in consanguineous couples this risk is much higher, and mutation screening in spouses of proven carriers may be indicated.

3.5. Prenatal Diagnosis {#sec3.5}
-----------------------

Prenatal diagnosis of FA is relatively straightforward after the pathogenic mutations in a given family have been identified. Fetal cells can be obtained by chorionic villus sampling (CVS) during weeks 10--12 of the pregnancy or by amniocentesis, which is performed between weeks 14 and 16. However, CVS may be preferred as the diagnosis will be known at an earlier stage. If the mutation is not known, a chromosomal breakage test on fetal material may be performed \[[@B34]\], but this test may be considered less reliable than screening for mutations in the fetal material. Alternatively, flow cytometric testing of MMC sensitivity in amniotic cell cultures might be an option; however this technique is only available in a limited number of specialized laboratories \[[@B35]\]. Occasionally, FA may be suspected by fetal ultrasound imaging and confirmed by parental carrier testing when the family is not yet known to carry a risk for FA \[[@B36]\].

3.6. Genotype-Phenotype Correlation {#sec3.6}
-----------------------------------

FA is considered as one disease, and the question may be raised whether all fifteen genetic subtypes equally conform to the clinical FA phenotype. Genotype-phenotype correlation studies comparing the 3 most common groups A, C, and G indicated modest phenotypic differences, which were rather correlated with the relative severity of the mutations \[[@B37]\]. However, bias due to the ethnic distribution of the studied population is very well possible. Other studies reported significant differences between FA-A/G versus FA-C \[[@B38]\]. Cases in group FA-D1 (mutated in BRCA2) and FA-N (mutated in *PALB2*) present with a distinct, relatively severe, phenotype that is characterized by the development of leukemia at very young age (median 2.2 years) and by pediatric cancers such as nephroblastoma (Wilms tumor) or medulloblastoma \[[@B17]--[@B21]\]. The observations that one of the pathogenic mutations in *BRCA2* in FA-D1 patients is hypomorphic and that mice with biallelic null alleles in *Brca2* are embryonic lethals suggest that the BRCA2 protein serves a function that is essential for survival.

Different mutations in the same gene may be associated with divergent phenotypes, as illustrated by the two *FANCC* mutations, c.711+4A\>T and c.67delG. The former (splice-site) mutation is associated with a relatively severe phenotype in Ashkenazi Jewish people \[[@B39]\] although the associated phenotype was reportedly less severe in patients of Japanese ancestry \[[@B40]\]. The carrier frequency for this mutation in the Ashkenazi population is relatively high (1 in 87), which has led to the recommendation of carrier detection to prevent disease \[[@B41]\]. In the Netherlands more than 50% of FA cases are homozygous for the *FANCC* frameshift mutation c.67delG. The phenotype associated with this mutation, like other exon 1 mutations, seems relatively mild, as these patients rarely have skeletal abnormalities and show a relatively late age of onset of their marrow failure \[[@B42]\]. Awareness of such genetically determined phenotypic differences may help in clinical decision making, including the counselling of patients and families.

3.7. Cancer Risk in Heterozygous Mutation Carriers {#sec3.7}
--------------------------------------------------

An important issue is whether FA mutation carriers are at increased risk to develop cancer or other types of disease. Overall, there is no increased risk for cancer among FA heterozygotes \[[@B43], [@B44]\]. However, the situation is different in some of the less prevalent FA subtypes. The FA-D1 subtype is caused by mutations in *BRCA2* \[[@B45]\] which is a well-known breast and ovarian cancer predisposition gene \[[@B46]\]. In FA-D1 one of the mutations will be hypomorphic because biallelic "severe" mutations are supposed to be lethal \[[@B24]\]. Therefore, one of the parents of a FA-D1 patient will be a heterozygous carrier of a "severe" inactivating *BRCA2*mutation and may thus have an increased risk for breast cancer and other BRCA2-associated cancers. Whether the parent with the hypomorphic mutation is also at increased risk is unknown: in breast cancer families these hypomorphic mutations are considered as variants with unknown clinical significance. Two other genes involved in FA and related to breast or ovarian cancer predisposition are *PALB2/FANCN* \[[@B47], [@B48]\] and *RAD51C/FANCO* \[[@B49]\]. Although cancer patients have been identified with germ-line mutations in these genes, an accurate estimate of the relative cancer risk for mutation carriers is still lacking.

Another special case is represented by female *FANCB* mutation carriers, who are supposed to consist of 50% FA-like cells due to silenced expression of the wild type *FANCB* allele by the random process of X inactivation that occurs during early embryonic development. Nevertheless, in the few female *FANCB* mutation carriers studied so far, inactivation appeared strongly skewed towards the mutated allele \[[@B50]\]. This suggests that FA cells have a poor chance to survive next to unaffected cells in the same tissue, and these FA cells may therefore not give an increased cancer risk. However, the data are scarce at present so that no firm conclusions can be drawn regarding the cancer risk of female *FANCB* mutation carriers \[[@B43]\].
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###### 

Fanconi anemia complementation groups, genes, and proteins.

  Group        Gene symbol(s)^a^   Cytogenetic location   Protein (amino acids)   Domain structure (references)
  ------------ ------------------- ---------------------- ----------------------- -------------------------------------------------
  A            *FANCA*             16q24.3                1455                    HEAT repeats \[[@B51]\]
  B            *FANCB*             Xp22.31                859                     ---
  C            *FANCC*             9q22.3                 558                     HEAT repeats \[[@B51]\]
  **D1** ^b^   *BRCA2*             13q12.3                3418                    RAD51- and DNA-binding motifs \[[@B52]\]
  D2           *FANCD2*            3p25.3                 1451                    ---
  E            *FANCE*             6p21.3                 536                     ---
  F            *FANCF*             11p15                  374                     ---
  G            *FANCG*             9p13                   622                     Tetratricopeptide repeats (TPR) \[[@B30]\]
  I            *FANCI*             15q26.1                1328                    ---
  **J** ^b^    *BRIP1*             17q22                  1249                    DNA helicase \[[@B53], [@B54]\]
  L            *FANCL*             2p16.1                 375                     RING finger motif (E3 ligase) \[[@B7], [@B51]\]
  M            *FANCM*             14q21.3                2014                    DNA helicase, nuclease \[[@B55]\]
  **N** ^b^    *PALB2*             16p12.1                1186                    ---
  **O** ^b^    *RAD51C*            17q25.1                376                     ---
  **P** ^b^    *SLX4*              16p13.3                1834                    Endonuclease scaffold \[[@B3], [@B4]\]

^a^For gene nomenclature see <http://www.genenames.org/>.

^b^The proteins defective in groups D1, J, N, O, and P (boldface) act downstream or independent of the monoubiquitination of FANCD2; all other FA proteins act upstream of this process.

###### 

Major recurrent mutations in FA.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene                                        Mutation\*                                        Geographic/ethnic background                                            Comment                                                                                References
  ------------------------------------------- ------------------------------------------------- ----------------------------------------------------------------------- -------------------------------------------------------------------------------------- --------------------
  *FANCA*                                     c.3788_3790del (p.Phe1263del)                     European, Brazilian                                                     Relatively mild                                                                        \[[@B56], [@B57]\]

  c.1115_1118delTTGG (p.Val372fs)             European                                          Relatively mild                                                         \[[@B58]\]                                                                             

  Exon 12--17del\                             South-African                                     Relatively common in Afrikaners                                         \[[@B59]\]                                                                             
  Exon 12--31del                                                                                                                                                                                                                                               

  c.295C\>T (p.Gln99X)                        Spanish Gypsy population                          Worldwide highest prevalence of mutant *FANCA* allele                   \[[@B60]\]                                                                             

  *FANCC*                                     c.711+4A\>T (originally reported as IVS4+4A\>T)   Homozygous in 80% of Ashkenazi Jewish FA; relatively common in Japan.   Severe phenotype in Jews, milder in Japanese.                                          \[[@B39]--[@B62]\]

  c.67delG (originally reported as 322delG)   Homozygous in approx. 50% of Dutch FA patients    Like other exon 1 mutations, relatively mild phenotype.                 \[[@B39], [@B37]--[@B63]\]                                                             

  *FANCD2*                                    c.1948-16T\>G                                     Turkish                                                                 Founder mutation                                                                       \[[@B24]\]

  *FANCG*                                     c.313G\>T (p.Glu105X)                             European                                                                44% of mutated *FANCG* alleles in Germany.                                             \[[@B64]\]

  c.1077-2A\>G                                Portuguese/Brazilian                              Founder mutation                                                        \[[@B64], [@B65]\]                                                                     

  c.1480+1G\>C                                French-Canadian                                   Founder mutation                                                        \[[@B65]\]                                                                             

  c.307+1G\>C                                 Japanese                                          Founder mutation                                                        \[[@B65], [@B66]\]                                                                     

  c.1794_1803del (p.Trp599fs)                 European                                                                                                                  \[[@B65]\]                                                                             

  c.637_643del (p.Tyr213fs)                   Sub-Saharan Africa                                82% of all black FA patients                                            \[[@B67]\]                                                                             

  *FANCJ*                                     c.2392C\>T (p.Arg798X)                                                                                                    Found in ca. 50% of FA-J patients of diverse ancestry; ancient mutation or hot spot.   \[[@B53], [@B54]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Nucleotide numbering based on [A]{.ul}TG = +1.

Published sequence variations in FA genes, with their descriptions conforming to the current nomenclature rules, are listed at [http://www.rockefeller.edu/fanconi/](http://www.rockefeller.edu/fanconi/.).

###### 

Mutations detected in a cohort of 54 patients by screening *FANCA, FANCC, FANCE, FANCF* and *FANCG.*

                    Allele 1                            Allele 2                                       
  ---- ---- ------- -------------------- -------------- ---------- -------------------- -------------- -------
  1    ES   FANCA   ex16_17del           del            12x        c.1115_1118del       p.Val372fs     62x
  2    PT   FANCA   c.718C\>T            p.Gln240X      2x         c.2870G\>A           W957X          1x
  3    NL   FANCA   ex15del              del            3x         ex15del              del            3x
  4    NL   FANCA   c.3788_3790del       p.Phe1263del   215x       c.3788_3790del       p.Phe1263del   215x
  5    CA   FANCA   c.718C\>T            pGlnx240X      2x         c.1085T\>C           p.Leu362Pro    novel
  6    PT   FANCA   c.3788_3790del       p.Phe1263del   215x       c.4130C\>G           p.Ser1377X     1x
  7    IE   FANCA   c.2812_2830dup       p.Asp944fs     3x         c.2812_2830dup       p.Asp944fs     3x
  8    AU   FANCA   c.2303T\>C           p.Leu768Pro    5x         c.2303T\>C           p.Leu768Pro    5x
  9    NL   FANCA   c.862G\>T            p.Glu288X      1x         c.862G\>T            p.Glu288X      1x
  10   NL   FANCA   ex11_33del           del            1x         c.2121delC           p.Asn707fs     novel
  11   DK   FANCA   ex1_8del             del            1x         c.3788_3790del       p.Phe1263del   215x
  12   UK   FANCA   c.337_338del         p.Ala114fs     1x         c.3349A\>G           p.Arg1117Gly   2x
  13   UK   FANCA   c.3568C\>T           p.Gln1190X     novel      c.3568C\>T           p.Gln1190X     novel
  14   NL   FANCA   c.487delC            p.Arg163fs     1x         c.2851C\>T           p.Arg951Trp    11x
  15   SE   FANCA   c.88delG             p.Val30fs      novel      c.100A\>T            p.Lys34X       2x
  16   NL   FANCA   c.862G\>T            p.Glu288X      9x         c.1771C\>T           p.Arg591X      9x
  17   PT   FANCA   c.1709_1715+4del     p.Glu570fs     novel      c.3430C\>T           p.Arg1144Trp   novel
  18   NO   FANCA   c.100A\>T            p.Lys34X       2x         c.1378C\>T           p.Arg460X      novel
  19   PT   FANCA   ex15_17del           del            2x         ex15_17del           del            2x
  20   NL   FANCA   c.2982-192A\>G       splice^2^      novel      ex7_31del            del            
  21   AU   FANCA   c.427-8_427-5del     splice         novel      c.1771C\>T           p.Arg591X      9x
  22   AU   FANCA   c.3491C\>T           p.Pro1164Leu   novel      c.3491C\>T           p.Pro1164Leu   novel
  23   CA   FANCA   ex4_29del            del            novel      ex31del              del            6x
  24   NL   FANCA   c.3391A\>G           p.Thr1131Ala   15x        c.3391A\>G           p.Thr1131Ala   15x
  25   GR   FANCA   c.2T\>C              p.Met1?        1x         c.3788_3790del       p.Phe1263del   215x
  26   IE   FANCA   c.851dup             p.Val285fs     novel      c.2534T\>C           p.Leu845Pro    4x
  27   NL   FANCA   c.2852G\>A           p.Arg951Gln    6x         c.3624C\>T           p.= (splice)   2x
  28   AU   FANCA   c.331_334dup         p.Leu112fs     novel      ex22_29del           del            novel
  29   NL   FANCA   c.862G\>T            p.Glu288X      9x         c.3920delA           p.Gln1307fs    2x
  30   IR   FANCA   ex21del              del            novel      ex21del              del            novel
  31   SE   FANCA   ex1_12del            del            novel      ex22_29del           del            novel
  32   NL   FANCB   c.755_767del         p.Leu252fs     novel      ---                  ---            ---
  33   NL   FANCC   c.67delG             p.Asp23fs      50x        c.553C\>T            p.Arg185X      14x
  34   NL   FANCC   c.67delG             p.Asp23fs      50x        c.67delG             p.Asp23fs      50x
  35   CA   FANCC   c.67delG             p.Asp23fs      50x        c.553C\>T            p.Arg185X      14x
  36   NL   FANCC   c.67delG             p.Asp23fs      50x        c.1155-1G\>C         splice         novel
  37   NL   FANCC   c.67delG             p.Asp23fs      50x        c.67delG             p.Asp23fs      50x
  38   NL   FANCC   c.67delG             p.Asp23fs      50x        c.467delC            p.Ser156fs     novel
  39   PT   FANCE   c.1111C\>T           p.Arg371Trp    6x         c.1111C\>T           p.Arg371Trp    6x
  40   UK   FANCF   c.496C\>T            p.Gln166X      4x         c.496C\>T            p.Gln166X      4x
  41   UK   FANCG   c.307+2delT          splice         novel      c.307+2delT          splice         novel
  42   UK   FANCG   c.1471_1473delinsG   p.Lys491fs     novel      c.1471_1473delinsG   p.Lys491fs     novel
  43   NL   FANCG   c.65G\>C             p.Arg22Pro     6x         c.65G\>C;            p.Arg22Pro     6x
  44   IR   FANCG   c.307+1G\>C          splice         21x        c.307+1G\>C          splice         21x
  45   NL   FANCG   c.85-1G\>A           splice         novel      c.85-1G\>A           splice         novel

^1^Country of origins: AU: Australia; CA: Canada; DK: Denmark; ES: Spain; GR: Greece; IE: Ireland; IR: Iran; NL: Netherlands; PT: Portugal; SE: Sweden; UK: United Kingdom

Number of database entries refers to the FA database at: <http://www.rockefeller.edu/fanconi/.>

The pathogenic state of novel missense mutations is based upon *in silico* prediction algorithms (SIFT, POLYPHEN2, Align GVGD), the presence of a second clearly pathogenic mutation in the same gene and segregation in the family.

^2^Effect c.2982-192A\>G: by studying cDNA it was shown that the mutation created a new splice donor site resulting in an aberrant mRNA.

###### 

Primers and conditions for PCR on genomic DNA of the coding sequence plus intron/exon boundaries of *FANCA, FANCC, FANCE, FANCF, FANCG,*and*FANCB.*

###### 

\(a\)

  *FANCA*                                                         
  ------------- ------------------------------------------------- -----
  FANCA_ex1F    gtaaaacgacggccag GCGCCTCCCCCAGGACCAACA            362
  FANCA_ex1R    caggaaacagctatga AGGCTCTGGCGGGAAGGGATCGG          
  FANCA_ex2F    gtaaaacgacggccag CTCTTCGGGAGGGTGTCGCTGGT          328
  FANCA_ex2R    caggaaacagctatga CTCTTCGGGAGGGTGTCGCTGGT          
  FANCA_ex3F    gtaaaacgacggccag GCCTGGCCTGGAGCTTGAAT             392
  FANCA_ex3R    caggaaacagctatga CGCAGGTTGAATCAGACGCTGTT          
  FANCA_ex4F    gtaaaacgacggccag TAAGGCATTTTAAACAGCAAGTC          430
  FANCA_ex4R    caggaaacagctatga TGCCAATAAATACTGAGCAAACT          
  FANCA_ex5F    gtaaaacgacggccag AGTATTGTTTCAGGTAATTTGTT          356
  FANCA_ex5R    caggaaacagctatga TGAAGGTACTTCTTTCCAATCCA          
  FANCA_ex6F    gtaaaacgacggccag AGATGTGTTTCAGGCTCTAAGTT          402
  FANCA_ex6R    caggaaacagctatga GCAATGCAATCTAGTCTAGTACA          
  FANCA_ex7F    gtaaaacgacggccag TGGGATTTAGTTGAGCCTTACGTCTGC      421
  FANCA_ex7R    caggaaacagctatgaAAGGTGAATGGAAACACTTAAACTCATGTCA   
  FANCA_ex8F    gtaaaacgacggccag GTGGTCAGGTGAGCAGTAACTTC          401
  FANCA_ex8R    caggaaacagctatga TAAATAGGTACAAACAGCACGTT          
  FANCA_ex9F    gtaaaacgacggccag TTCTCTTGTGTGATGCAGGTATC          332
  FANCA_ex9R    caggaaacagctatga TGACCCACAGATTCATGAGGTAT          
  FANCA_ex10F   gtaaaacgacggccag TTTTGATTAAGGCCTACAGATTG          406
  FANCA_ex10R   caggaaacagctatga CCTCCTCCTCACGCACGTTATCG          
  FANCA_ex11F   gtaaaacgacggccag TTTCAAGTCTGTGGTTATAGTGG          410
  FANCA_ex11R   caggaaacagctatga AGACGTAAAAGAGGTCCTAGAAT          
  FANCA_ex12F   gtaaaacgacggccag CTGTGGGGCTGGTCCTTAACAAA          236
  FANCA_ex12R   caggaaacagctatga AGGCAGCATGACAAGTACTAGGC          
  FANCA_ex13F   gtaaaacgacggccag ACATTGGTTTGCTTGGATATTGA          377
  FANCA_ex13R   caggaaacagctatga CTGACAAAGAATGTTCCATCGAC          
  FANCA_ex14F   gtaaaacgacggccag TGCTGTAATTGCTGTGTAGTCTT          411
  FANCA_ex14R   caggaaacagctatga ACTCACATGACAGAGAATCAGGT          
  FANCA_ex15F   gtaaaacgacggccag ACTACAGCAGCCGCCCGGACACT          430
  FANCA_ex15R   caggaaacagctatga GCAGATCTGCAGGAGGCTCTTGG          
  FANCA_ex16F   gtaaaacgacggccag TCCCAGGCAGTTCCCAGACTAAC          312
  FANCA_ex16R   caggaaacagctatga AGCTGATGACAAATCCTCGTAGA          
  FANCA_ex17F   gtaaaacgacggccag ACCGCTCCCTCCTCACAGACTAC          334
  FANCA_ex17R   caggaaacagctatga AAGGCTGAAAAACTCAACTCAAG          
  FANCA_ex18F   gtaaaacgacggccag GCGCACAGCATGTGGGCCTTTAC          397
  FANCA_ex18R   caggaaacagctatga GCAGCTGCTAGAGGCCTTTTCGG          
  FANCA_ex19F   gtaaaacgacggccag GTGCACAAGAAGACTTCATAATG          284
  FANCA_ex19R   caggaaacagctatga AGTCCTTGCTTTCTACACAACTG          
  FANCA_ex20F   gtaaaacgacggccag CTTCTCTGTGTTGCAGCATATTC          298
  FANCA_ex20R   caggaaacagctatga AGAAGAAACCTGGAAGTAGTCAT          
  FANCA_ex21F   gtaaaacgacggccag ATAATAGATTTGGGGATTGTAAT          255
  FANCA_ex21R   caggaaacagctatga CAACAGACACTCAAGGTTAGGAA          
  FANCA_ex22F   gtaaaacgacggccag TGCAGTGAAGAGTCCTGTTGAGT          305
  FANCA_ex22R   caggaaacagctatga ACACACCAGCCTGATGTCACTAT          
  FANCA_ex23F   gtaaaacgacggccag CAGTCAGCAGGATCCGTGGAATC          416
  FANCA_ex23R   caggaaacagctatga GGCCCTGGAACATCTGATACGAC          
  FANCA_ex24F   gtaaaacgacggccag CCTTCCTGCTGCTCCCGTCC             229
  FANCA_ex24R   caggaaacagctatga CAGACTTGGCCCAGCAAGAG             
  FANCA_ex25F   gtaaaacgacggccag CCGCTGGTGGTTGGATTAGCTGT          296
  FANCA_ex25R   caggaaacagctatga TTTCCAGGGCACTGAAGACGAAT          
  FANCA_ex26F   gtaaaacgacggccag AGCTTGGAAGAGGGCAGTCTGCT          347
  FANCA_ex26R   caggaaacagctatga CTCTTCTAATTTTATCAAACGAG          
  FANCA_ex27F   gtaaaacgacggccag AGACTGTCTCACAACAAACGAAC          356
  FANCA_ex27R   caggaaacagctatga CGGTCCGAAAGCTGCGTAAAC            
  FANCA_ex28F   gtaaaacgacggccag GTTGATGGTCTGTTTCCACCTGA          401
  FANCA_ex28R   caggaaacagctatga GAAGGAACGGTCACCTACGTGCT          
  FANCA_ex29F   gtaaaacgacggccag GACATGGAGGACTGCGTATGAGA          411
  FANCA_ex29R   caggaaacagctatga GTGGCTGTGATGACTGGAACGTG          
  FANCA_ex30F   gtaaaacgacggccag CCCGAGCCGCCAGTCTCAACCCA          411
  FANCA_ex30R   caggaaacagctatga AAAGGCAGACCCACCCTAAGCTA          
  FANCA_ex31F   gtaaaacgacggccag GATAAGCCTCCTTGGTCATGGTA          406
  FANCA_ex31R   caggaaacagctatga TGGCAATAAATATCTTAATAGCA          
  FANCA_ex32F   gtaaaacgacggccag TTCCTGTGCCAGCATACTGCTCT          359
  FANCA_ex32R   caggaaacagctatga GGGTGGGGACACACAGACAAGTA          
  FANCA_ex33F   gtaaaacgacggccag TGGGTTTCAGGGTGGTGGTTGCT          356
  FANCA_ex33R   caggaaacagctatga GAACCCTTTCCTCAGTAATTCAC          
  FANCA_ex34F   gtaaaacgacggccag CGCCCAGGGAAGCCGTTAAGTTT          333
  FANCA_ex34R   caggaaacagctatga GCGTTCTGAGAAGGCCACGAGAG          
  FANCA_ex35F   gtaaaacgacggccag TTCCTTCACTCTACTAGTTGTGG          311
  FANCA_ex35R   caggaaacagctatga TGAGATGGTAACACCCGTGATGG          
  FANCA_ex36F   gtaaaacgacggccag CCATCTCAGCCACCCTCATCTGT          350
  FANCA_ex36R   caggaaacagctatga AGGCGCCCACCACCACGAGAACT          
  FANCA_ex37F   gtaaaacgacggccag GACTTGGTTTCTATGGCGTGGTT          310
  FANCA_ex37R   caggaaacagctatga CCCAGAGAAATAGCACTGATTGA          
  FANCA_ex38F   gtaaaacgacggccag GTTTTCTAAGATCCACTTAAAGG          362
  FANCA_ex38R   caggaaacagctatga CTCACTCACACTTCCGCAAACAC          
  FANCA_ex39F   gtaaaacgacggccag CTGTCCAGAGGCCCAGTATTACC          387
  FANCA_ex39R   caggaaacagctatga AGGAGGGCTCGTTCTTAACCATT          
  FANCA_ex40F   gtaaaacgacggccag GGTGTCCCCAGCACTGATAATAG          353
  FANCA_ex40R   caggaaacagctatga AGACATAGTGACAAATGGCTACA          
  FANCA_ex41F   gtaaaacgacggccag CCCTTGGCATCACCTGCTACCTT          403
  FANCA_ex41R   caggaaacagctatga AACAGGCAAACTCACAGGTTAGA          
  FANCA_ex42F   gtaaaacgacggccag ACCAGCCCTGTTTCTGTATGTCT          248
  FANCA_ex42R   caggaaacagctatga ACATGGCCCAGGCAGCTGTCAAT          
  FANCA_ex43F   gtaaaacgacggccag TGTGGGGGACATGAGAATTGACA          378
  FANCA_ex43R   caggaaacagctatga GTAATCCACTTTTTAGTGCAACA          
  FANCAIVS10F   gtaaaacgacggccag TTTACATGTGCATCAGTTAGCTT          184
  FANCAIVS10R   caggaaacagctatga CATGAAGACACAGAAAAAGTAGGT         

###### 

\(b\)

  ----------------------------------------------------------------
  *FANCC*                                                    
  -------------- ------------------------------------------- -----
  FANCC_ex1F\    gtaaaacgacggccag ACCATTTCCTTCAGTGCTGGACA\   378
  FANCC_ex1R     caggaaacagctatga CCATCGGCACTTCAGTCAATACC    

  FANCC_ex2F\    gtaaaacgacggccag CTAAACAAGAAGCATTCACGTTC\   303
  FANCC_ex2R     caggaaacagctatga GGAGAAAGGTTCATAATGTAAGC    

  FANCC_ex3F\    gtaaaacgacggccag TCAGCAGAAAGAGAATGTGCAAA\   405
  FANCC_ex3R     caggaaacagctatga AACATCATAGAACTGGATTCCAC    

  FANCC_ex4F\    gtaaaacgacggccag TGTACATAAAAGGCACTTGCATT\   380
  FANCC_ex4R     caggaaacagctatga TCCCATCTCACATTTCTTCCGTA    

  FANCC_ex5F\    gtaaaacgacggccag AGAACTGATGTAATCCTGTTTGC\   367
  FANCC_ex5R     caggaaacagctatga TTACTGCTCTGTGAGAGTTGAGA    

  FANCC_ex6F\    gtaaaacgacggccag GTCTTTGACCTTTTTAGCATGAA\   387
  FANCC_ex6R     caggaaacagctatga AACGTTTGGACACTGCTGTCGTA    

  FANCC_ex7F\    gtaaaacgacggccag ATTAGTGATTGCATTTTGAACTT\   422
  FANCC_ex7R     caggaaacagctatga CAAAAATAAAATGTAAATACACG    

  FANCC_ex8F\    gtaaaacgacggccag CTCCTTTGGCTGATAATAGCAAG\   336
  FANCC_ex8R     caggaaacagctatga CTGATTTTTGAGTTTTTACCTCT    

  FANCC_ex9F\    gtaaaacgacggccag ATACTGCTGAAGCTTATGGCACA\   400
  FANCC_ex9R     caggaaacagctatga TAACCTTTGTTGGGGCACTCATT    

  FANCC_ex10F\   gtaaaacgacggccag TATGAGGTTATTGGGAGCTTATT\   382
  FANCC_ex10R    caggaaacagctatga CTGTCTCCCTCATGCTGTAGATA    

  FANCC_ex11F\   gtaaaacgacggccag GAACCAGAAGTAAAGGGCGTCTC\   416
  FANCC_ex11R    caggaaacagctatga CTGACCTGCTCCAAGCCATCCGT    

  FANCC_ex12F\   gtaaaacgacggccag AAGTACAATTTAAGCCAACCGTT\   451
  FANCC_ex12R    caggaaacagctatga AGGTTGCCATGACATATGCCATC    

  FANCC_ex13F\   gtaaaacgacggccag CCTCTCTCAGGGGCCAGTGCTTA\   435
  FANCC_ex13R    caggaaacagctatga AGACCCTCGGACAGGTAACCCAC    

  FANCC_ex14F\   gtaaaacgacggccag ACTTGCTATGCTAATCACCTTGC\   437
  FANCC_ex14R    caggaaacagctatga AATGCGTGGCCACAGGTCATCAC    
  ----------------------------------------------------------------

###### 

\(c\)

  ----------------------------------------------------------------
  *FANCE*                                                    
  -------------- ------------------------------------------- -----
  FANCE_ex1F\    gtaaaacgacggccag CGCCTCCCTCCTTCCCTTTC\      540
  FANCE_ex1R     caggaaacagctatga CCCGCCTCCCATACCTGCTAA      

  FANCE_ex2aF\   gtaaaacgacggccag GCTCTGCCCAGTCTGCCTTGTGC\   469
  FANCE_ex2aR    caggaaacagctatga CTCTGAGTCCTTTCTGCGTTTCC    

  FANCE_ex2bF\   gtaaaacgacggccag GCCAGAGACAGCTCCAAAGTCTA\   479
  FANCE_ex2bR    caggaaacagctatga CAGCCTTCCCCATGGATAAAGCC    

  FANCE_ex3F\    gtaaaacgacggccag GCCTCTTGACTTTCTTGAATCAT\   352
  FANCE_ex3R     caggaaacagctatga ACTGTCCTCAGACCTTTACTCCA    

  FANCE_ex4F\    gtaaaacgacggccag TTGAACCAAGTGTAGACTTACCA\   436
  FANCE_ex4R     caggaaacagctatga GGGAAGGAACCAAGGGCTAAAAG    

  FANCE_ex5F\    gtaaaacgacggccag GTATCTTTTAGCCCTTGGTTCCT\   431
  FANCE_ex5R     caggaaacagctatga GAATCCCCTCTCTCAAGTACCAC    

  FANCE_ex6F\    gtaaaacgacggccag TTTCCTTTGTAACATGTATCATC\   433
  FANCE_ex6R     caggaaacagctatga AGCAGAAAGCAGGGAGGCGGTAA    

  FANCE_ex7F\    gtaaaacgacggccag ACAGGCTGGGCATTCTGTTACCG\   425
  FANCE_ex7R     caggaaacagctatga AGTGAGACACAAGGATCCCCTAA    

  FANCE_ex8F\    gtaaaacgacggccag TTGGAGCAGCAGATAGATACTCA\   380
  FANCE_ex8R     caggaaacagctatga AGAGGTGGAGCTGAAGTGACCAT    

  FANCE_ex9F\    gtaaaacgacggccag GTTACCTGCCCAGGGTCACCTAG\   388
  FANCE_ex9R     caggaaacagctatga CTGGCCAGCACTCAGGGTTTTAT    

  FANCE_ex10F\   gtaaaacgacggccag TGGCCTCCTCTCTCCTCAATAGA\   369
  FANCE_ex10R    caggaaacagctatga AACAGGGAGGCAGTTGCAATCTG    
  ----------------------------------------------------------------

###### 

\(d\)

  ----------------------------------------------------------------
  *FANCF*                                                    
  -------------- ------------------------------------------- -----
  FANCF_ex1aF\   gtaaaacgacggccag TTTCGCGGATGTTCCAATCAGTA\   449
  FANCF_ex1aR    caggaaacagctatga CTGCACCAGGTGGTAACGAGCTG    

  FANCF_ex1bF\   gtaaaacgacggccag AGTGGAGGCAAGAGGGCGGCTTT\   456
  FANCF_ex1bR    caggaaacagctatga GCTATCACCTTCAGGAAGTTGTT    

  FANCF_ex1cF\   gtaaaacgacggccag CCCAAATCTCCAGGAGGACTCTC\   444
  FANCF_ex1cR    caggaaacagctatga TTTCTGAAGGTCATAGTGCAAAC    

  FANCF_ex1dF\   gtaaaacgacggccag GCTTTTGACTTTAGTGACTAGCC\   456
  FANCF_ex1dR    caggaaacagctatga ATTTGGTGAGAACATTGTAATTT    
  ----------------------------------------------------------------

###### 

\(e\)

  ----------------------------------------------------------------
  *FANCG*                                                    
  -------------- ------------------------------------------- -----
  FANCG_ex1F\    gtaaaacgacggccag AGCCTGGGCGGGTGGATTGGGAC\   389
  FANCG_ex1R     caggaaacagctatga TCATTTCTGGCTCTTTGGTCAAG    

  FANCG_ex2F\    gtaaaacgacggccag CAGGCCAAGGTAACACGGTTGCT\   460
  FANCG_ex2R     caggaaacagctatga CCAGTCTCCTCTGTGCCTTAAAC    

  FANCG_ex3F\    gtaaaacgacggccag TATTGTAGCTGTTTTGGTTGGAG\   362
  FANCG_ex3R     caggaaacagctatga GGTGACAGATGTTGTTTATCCTC    

  FANCG_ex4F\    gtaaaacgacggccag GGAGATGGAGGATGAGGTGCTAC\   411
  FANCG_ex4R     caggaaacagctatga CGACCACCAACCCAGCCGCCTGT    

  FANCG_ex5F\    gtaaaacgacggccag AGATGGAGATAGGAGAAGACGAG\   454
  FANCG_ex5R     caggaaacagctatga GCTTCATGAAGGCTGCTTAGTGC    

  FANCG_ex6F\    gtaaaacgacggccag CAGTTCCATGGGCTTCTTAGACC\   393
  FANCG_ex6R     caggaaacagctatga TCAGGGCTGCAACCAAGTACAAC    

  FANCG_ex7F\    gtaaaacgacggccag GCACTGGGGTCCTGTCACCGTAA\   418
  FANCG_ex7R     caggaaacagctatga ATAATCTTTGGGAGCCATACTTC    

  FANCG_ex8F\    gtaaaacgacggccag GCTTGTGATGGGGTGACTTGACT\   438
  FANCG_ex8R     caggaaacagctatga AGTTCAGGTCTAGAAGCAAGGTA    

  FANCG_ex9F\    gtaaaacgacggccag CCTCCTCAGGGCCCATGAACATC\   400
  FANCG_ex9R     caggaaacagctatga GCAGTGTCTTGAAAGGCATGAGC    

  FANCG_ex10F\   gtaaaacgacggccag CAGGACTCTGCATGGTACCAG\     460
  FANCG_ex10R    caggaaacagctatga CCAATCAGAAAATCATCCCTC      

  FANCG_ex11F\   gtaaaacgacggccag AGCTCCATGTTCACCTACTTACC\   397
  FANCG_ex11R    caggaaacagctatga CAGTGCCGCATCTGACTTACATC    

  FANCG_ex12F\   gtaaaacgacggccag AGGATTTGGGGTTTTGGTGACTG\   445
  FANCG_ex12R    caggaaacagctatga AACTCTTGGGAGCCCTGCATACA    

  FANCG_ex13F\   gtaaaacgacggccag CCGCTTCCATATGTGAGTGTAGG\   340
  FANCG_ex13R    caggaaacagctatgaC CACAATAGGTCCAAGGACTCTA    

  FANCG_ex14F\   gtaaaacgacggccag CCAAACTAAGGGGTCACATGAAG\   405
  FANCG_ex14R    caggaaacagctatga GATGGTGAAGCAGAAAGCCCTCC    
  ----------------------------------------------------------------

###### 

\(f\)

  -----------------------------------------------------------------------------------------------------------
  *FANCB*                                                                                               
  -------------- -------------------------------------------------------------------------------------- -----
  FANCB_ex3AF\   gtaaaacgacggccag GATATGGTTATTTGAATTCTTAGCAcaggaaacagctatga GCCATCCTTCATCTCATAGCCTAGT   721
  FANCB_ex3AR                                                                                           

  FANCB_ex3BF\   gtaaaacgacggccag ATTAACCTCCCTTACATTGTGATAGcaggaaacagctatga CAATAAGACTCCAGAATGAACTCTA   811
  FANCB_ex3BR                                                                                           

  FANCB_ex4F\    gtaaaacgacggccag TTTACAAATGACAACTACATGAcaggaaacagctatga TTAAGTATAAAACCACCAATAT         391
  FANCB_ex4R                                                                                            

  FANCB_ex5F\    gtaaaacgacggccag ACTGCATCTGGCCTATAGTTcaggaaacagctatga AATACCATTTTTACCCAAGC             411
  FANCB_ex5R                                                                                            

  FANCB_ex6F\    gtaaaacgacggccag GTATTTCCTGAATTATTGGTATGTC\                                            395
  FANCB_ex6R     caggaaacagctatga CATAAAAGTCCACCATTATAACCTC                                             

  FANCB_ex7F\    gtaaaacgacggccag TGTTTGGGCCATAAGCCCTA\                                                 355
  FANCB_ex7R     caggaaacagctatga TTCTGGAGCATCAAGACAGT                                                  

  FANCB_ex8F\    gtaaaacgacggccag GTTGTTTGTATGACATTTAATCATC\                                            636
  FANCB_ex8R     caggaaacagctatga ATCATTAAACTCTGCCCATTATCAG                                             

  FANCB_ex9F\    gtaaaacgacggccag AGGTAATTTTGTTGGCACTT\                                                 531
  FANCB_ex9R     caggaaacagctatga ATGCGTTCATTCATGCTAGG                                                  

  FANCB_ex10F\   gtaaaacgacggccag AATTGGTTCTGTTTATCATTATGGT\                                            686
  FANCB_ex10R    caggaaacagctatga CTACTACAGTAAGCCTCGGTGTTTA                                             
  -----------------------------------------------------------------------------------------------------------

PCR conditions:

PCR was performed in Applied Biosystems PE9700 system using 96-well plates. PCR reactions (final volume 25 *μ*l) contained 0.5 units Platinum Taq polymerase (Invitrogen), 1,5 mM MgCl~2~, 0.2 mM NTPs (Invitrogen), and 10 pmol primer.

For the large majority of amplicons, standard PCR conditions were used: preheat 95°C, 5 min, denaturation 95°C, 30 sec, annealing 60°C, 30 sec., elongation 72°C, 1 min, number of cycles: 33.

Fragments with a different annealing temperature were *FANCA* exons 5, 7, 13, 21, 26, 31, and 38, *FANCC* exon 7, *FANCF* fragment 1d and *FANCE* exon 1 : 55°C; *FANCA* exon 1 : 64°C. For *FANCE* exon 1 the PCR mix was supplemented with 10% DMSO.

For *FANCB* different PCR conditions were used: preheat 95°C, 5 min, denaturation 95°C, 1 min, annealing 50°C, 1 min., elongation 72°C, 1 min., number of cycles 30. For *FANCB* exon 7 and 9 the annealing temperature was 55°C. For sequencing of exon 7 forward, a special sequencing primer was used: 5′-TTTTTAGAAGGAATGTCTTG-3′.

FA gene specific part of the primer is indicated in capitals. Primers are extended with M13 sequence (indicated in normal letter type), which is used for the sequencing reaction.

[^1]: Academic Editor: Stefan Meyer
